Clinical Trial Update: PS-341 in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating PS-341 (bortezomib) in metastatic renal cell carcinoma (kidney cancer) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• PS-341 (bortezomib) (bortezomib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED